Clinical trial • Phase IV • Other

Ferrous sulfate for Iron deficiency

Phase IV trial of Ferrous sulfate for Iron deficiency.

Overview

Trial Therapeutic Area
Other
Trial Disease
Iron deficiency
Trial Stage
Phase IV
Drug Modality
Small molecule
Paediatric Trial
Yes

Key dates

Initial CTIS Submission Date
13-02-2026
First CTIS Authorization Date
14-04-2026

Trial design

Randomised, active intervention: duroferon 100 mg administered on alternate days in combination with iron smart. comparator arm: duroferon placebo plus iron smart (placebo arm).-controlled Phase IV trial in Sweden.

Randomised
Yes
Comparator
Active intervention: Duroferon 100 mg administered on alternate days in combination with Iron Smart. Comparator arm: Duroferon placebo plus Iron Smart (placebo arm).
Target Sample Size
279

Eligibility

Recruits 279 paediatric patients.

Pregnancy Exclusion
Pregnancy
Vulnerable Population
Participants are adolescent girls (includes minors). Written informed consent is required from the participant; written informed consent from legal guardian(s) is required if the participant is <18 years. A re-consent procedure at 18 years is documented (L1_Re-consent_18 years).

Inclusion criteria

  • {"criterion_text":"- Student at Polhemskolan, Lund\n- Age ≥15 years\n- Post-menarcheal\n- Written informed consent from the participant\n- Written informed consent from legal guardian(s) if <18 years\n- Serum ferritin <30 µg/L"}

Exclusion criteria

  • {"criterion_text":"- Pregnancy\n- Chronic inflammatory disease (e.g. rheumatoid arthritis, Crohn’s disease)\n- Ongoing acute infection (e.g. tonsillitis, urinary tract infection)\n- CRP >10 mg/L\n- Current iron supplementation (except multivitamins)\n- Anaemia (Hb <110 g/L if <18 years; <117 g/L if ≥18 years, according to regional reference limits)\n- Iron overload (serum ferritin >150 µg/L; WHO definition)\n- Clinically significant vitamin B12 deficiency requiring immediate medical evaluation or treatment (e.g. serum vitamin B12 <150 pmol/L).\n- Use of medication known to interfere with iron absorption or cause clinically significant interaction with oral iron (e.g. fluoroquinolones, tetracyclines, bisphosphonates, levodopa, methyldopa, aluminium- or magnesium-containing antacids), defined as regular or daily use (≥3 times per week)."}

Endpoints

Primary endpoints

  • {"endpoint_text":"- 1. Feasibility, including recruitment, retention, adherence and tolerability.\n- 2. Diagnostic performance of IRON-5 (sensitivity, specificity, positive and negative predictive values, and ROC-AUC).","definition_or_measurement_approach":"Feasibility measured by recruitment, retention, adherence and tolerability metrics. Diagnostic performance of IRON-5 measured by sensitivity, specificity, positive and negative predictive values and ROC-AUC versus ferritin-defined iron deficiency (ferritin <15 µg/L)."}

Secondary endpoints

  • {"endpoint_text":"- Change in ferritin concentration.\n- Change in haemoglobin, TSAT, vitamin B12 and 25-hydroxyvitamin D from screening to follow-up.\n- Associations between iron deficiency and selected factors (dietary patterns, BMI, menstrual characteristics including bleeding volume, menstrual pain and analgesic use, hormonal contraceptive use, physical activity, socioeconomic status and country of birth).\n- Associations between fatigue and self-rated QoL and factors other than iron deficiency (e.g. vitamin B12 and vitamin D deficiency, anxiety/depression and lifestyle factors).","definition_or_measurement_approach":"Change endpoints assessed from screening to follow-up for laboratory measures (ferritin, haemoglobin, TSAT, vitamin B12, 25-hydroxyvitamin D). Association endpoints explored using collected questionnaire and clinical data (dietary patterns, BMI, menstrual characteristics, physical activity, socioeconomic status, country of birth, fatigue and QoL measures)."}

Recruitment

Digital Remote Recruitment
Yes
Planned Sample Size
279
Recruitment Window Months
9
Consent Approach
Written informed consent from the participant is required. For participants <18 years, written informed consent from legal guardian(s) is required. A re-consent process at 18 years is documented (L1_Re-consent_18 years). Participant information and consent forms are provided (documents L1_SIS_trial participant and L1_SIS_Legal_guardian). Languages available are not specified in the record.

Methods

  • School-based recruitment: inclusion criterion specifies 'Student at Polhemskolan, Lund' indicating recruitment at Polhemskolan, Lund (Sweden).
  • Recruitment materials: recruitment poster and other recruitment materials (document titles include 'K2_Recruitment poster_DRAFT_IRONGIRLS-PILOT' and 'K2_Beskrivning av rekryteringsmaterial_IRONGIRLS-PILOT').
  • Digital/app-related: use of the Iron Smart app (document 'L2_Beskrivning av Iron Smart-appen') as part of the study/intervention and recruitment information.

Geography

Total Number Of Sites
1
Total Number Of Participants
279

Sweden

Earliest CTIS Part Ii Submission Date
01-04-2026
Latest Decision Or Authorization Date
14-04-2026
Processing Time Days
13
Number Of Sites
1
Number Of Participants
279

Sites

Site Name
Region Skane
Department Name
Center for Primary Health Care Research, Nöbbelöv Primary Health Care Center, 22638 Lund
Contact Person Name
Moa Wolff
Contact Person Email
irongirls@med.lu.se

Sponsor

Primary sponsor

Full Name
Region Skane
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Sweden

Investigational products

Investigational Product Name
Duroferon depottabletter
Active Substance
Ferrous sulfate
Modality
Small molecule
Routes Of Administration
ORAL USE
Route
oral
Authorisation Status
Authorised (marketingAuthNumber: 5680; authorisationCountryCode: NO)
Starting Dose
100 mg
Dose Levels
100 mg
Frequency
Alternate days
Maximum Dose
100 mg
Investigational Product Name
Duroferon placebo
Modality
Other
Authorisation Status
No marketing authorisation (marketingAuthNumber: N/A; authorisationCountryCode: IS)
Combination Treatment
Yes

Related trials

Other published trials that may interest you.